| DAPAGLIFLOZIN |
211442 |
001 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
5MG |
No
|
No
|
2019/01/04
(TA)
|
--
|
APOTEX INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
211442 |
002 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
10MG |
No
|
No
|
2019/01/04
(TA)
|
--
|
APOTEX INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
211439 |
001 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
5MG |
No
|
No
|
2019/01/18
(TA)
|
--
|
HETERO LABS UNIT III |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
211439 |
002 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
10MG |
No
|
No
|
2019/01/18
(TA)
|
--
|
HETERO LABS UNIT III |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
211564 |
001 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
5MG |
No
|
No
|
2020/03/20
(TA)
|
--
|
GLENMARK GENERICS |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
211564 |
002 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
10MG |
No
|
No
|
2020/03/20
(TA)
|
--
|
GLENMARK GENERICS |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE |
211532 |
001 |
ANDA |
DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE |
TABLET; ORAL |
5MG |
No
|
No
|
2024/01/03
(TA)
|
--
|
LUPIN LTD |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE |
211532 |
002 |
ANDA |
DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE |
TABLET; ORAL |
10MG |
No
|
No
|
2024/01/03
(TA)
|
--
|
LUPIN LTD |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN |
218091 |
002 |
ANDA |
DAPAGLIFLOZIN || METFORMIN |
TABLET |
5MG |
No
|
No
|
2025/05/08
(TA)
|
--
|
SINOTHERAPEUTICS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN |
218091 |
003 |
ANDA |
DAPAGLIFLOZIN || METFORMIN |
TABLET |
10MG |
No
|
No
|
2025/05/08
(TA)
|
--
|
SINOTHERAPEUTICS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN |
218091 |
004 |
ANDA |
DAPAGLIFLOZIN || METFORMIN |
TABLET |
500MG |
No
|
No
|
2025/05/08
(TA)
|
--
|
SINOTHERAPEUTICS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN |
218091 |
005 |
ANDA |
DAPAGLIFLOZIN || METFORMIN |
TABLET |
1000MG |
No
|
No
|
2025/05/08
(TA)
|
--
|
SINOTHERAPEUTICS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
219408 |
001 |
ANDA |
DAPAGLIFLOZIN |
TABLET |
5MG |
No
|
No
|
2026/01/08
(TA)
|
--
|
SCIEGEN PHARMACEUTICALS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
219408 |
002 |
ANDA |
DAPAGLIFLOZIN |
TABLET |
10MG |
No
|
No
|
2026/01/08
(TA)
|
--
|
SCIEGEN PHARMACEUTICALS INC |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
219755 |
002 |
ANDA |
DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE |
TABLET, EXTENDED RELEASE |
10MG |
No
|
No
|
2026/01/29
(TA)
|
--
|
INVENTIA HEALTHCARE LIMITED |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
219755 |
003 |
ANDA |
DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE |
TABLET, EXTENDED RELEASE |
5MG |
No
|
No
|
2026/01/29
(TA)
|
--
|
INVENTIA HEALTHCARE LIMITED |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
219755 |
004 |
ANDA |
DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE |
TABLET, EXTENDED RELEASE |
500MG |
No
|
No
|
2026/01/29
(TA)
|
--
|
INVENTIA HEALTHCARE LIMITED |
None (Tentative Approval) |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
219755 |
005 |
ANDA |
DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE |
TABLET, EXTENDED RELEASE |
2.5MG |
No
|
No
|
2026/01/29
(TA)
|
--
|
INVENTIA HEALTHCARE LIMITED |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
216119 |
001 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
5MG |
No
|
No
|
2026/04/02
(TA)
|
--
|
JIANGSU HANSOH PHARM |
None (Tentative Approval) |
| DAPAGLIFLOZIN |
216119 |
002 |
ANDA |
DAPAGLIFLOZIN |
TABLET;ORAL |
10MG |
No
|
No
|
2026/04/02
(TA)
|
--
|
JIANGSU HANSOH PHARM |
None (Tentative Approval) |